CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <\/p>\n
Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that Michael J. Pellini, M.D., president and chief executive officer, will present an overview of the company at the Lazard Capital Markets 9th Annual Healthcare Conference at the Pierre Hotel in New York City on Tuesday, November 13, 2012 at 9:30 am ET. <\/p>\n
Dr. Pellini will provide a corporate update on Foundation Medicine, including an overview of FoundationOne, the companys genomic assay for all solid tumors that helps physicians match patients with the targeted drugs or clinical trials that may be best suited for their unique cancer. <\/p>\n
About FoundationOne <\/p>\n
FoundationOne is a fully informative genomic profile that complements traditional cancer decision tools and often expands treatment options by matching each patient with targeted therapies that may be relevant to the molecular changes in their tumor. Using next-generation sequencing, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations including base substitutions, insertions, deletions, copy number alterations and select rearrangements. Each patients genomic profile is reported to the physician matched with targeted therapies and clinical trials that may be relevant based on the molecular blueprint of their tumor. Results are supported by the latest scientific and medical evidence. FoundationOne has been optimized to fit easily into the clinical workflow of a practicing oncologist. It is available for all solid tumors and clinical grade results can be obtained from as little as 50ng of DNA obtained from formalin-fixed, paraffin-embedded tumor tissue samples. FoundationOne is a laboratory-developed test performed at Foundation Medicines CLIA-certified facility and is currently available for all solid tumor types. Please visit http:\/\/www.foundationone.com<\/a> for more information. <\/p>\n About Foundation Medicine <\/p>\n Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patients unique cancer. The companys initial clinical assay, FoundationOne, is a fully informative genomic profile to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http:\/\/www.foundationmedicine.com<\/a>. <\/p>\n Foundation Medicine is a registered trademark, and FoundationOneTM is a trademark of Foundation Medicine, Inc. <\/p>\n<\/p>\n Read the rest here: <\/p>\n Foundation Medicine to Present at the Lazard Capital Markets 9th Annual Healthcare Conference<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that Michael J. Pellini, M.D., president and chief executive officer, will present an overview of the company at the Lazard Capital Markets 9th Annual Healthcare Conference at the Pierre Hotel in New York City on Tuesday, November 13, 2012 at 9:30 am ET. Continue reading